Baculovirus Produced P. falciparum Vaccine

Description The technology covers the construct consisting of the baculovirus polyhedron promoter, the yeast flg5 leader sequence, and the p42 MSP1 sequence with the transmembrane domain deleted cloned at the University of Hawaii from the Uganda-Palo Alto isolate of P. falciparum. The patent application also considers the production of other, related p42 constructs based on allelic and variant sequences expressed by other isolates of P. falciparum.

Applications Malaria vaccine.

Main Advantages The p42 MSP1 recombinant polypeptide produced by recombinant baculoviruses expressing this construct in insect cell culture possesses several properties which make it particularly attractive as a malaria vaccine: (1) reactivity with a panel of monoclonal antibodies produced against native, parasite MSP1 indicate that it possesses disulfide-dependent, conformational determinants which are characteristic of the native protein, (2) immunogenicity studies have indicated that it is highly immunogenic, inducing very high antibody titers in rabbits and non-human primates (Aotus) and priming both type 1 and type 2 cytokine responses (Aotus), (3) a vaccination study has demonstrated that BVp42, when combined with an adjuvant such as Complete Freund’s Adjuvant, induces a protective immune response against P. falciparum infection in non-human primates (Aotus).

Type of Offer: Licensing

Next Patent »
« More Medical Patents

Share on      

CrowdSell Your Patent